ACTRN12623000838617
Recruiting
Phase 2
An open label study to investigate the safety and feasibility of delivering 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy to patients with posttraumatic stress disorder
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Posttraumatic Stress Disorder
- Sponsor
- Emyria Ltd
- Enrollment
- 5
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Can provide a support person (relative, spouse, close friend, or other support person) who is willing and able to stay overnight with the participant following each Treatment Session, and who can be reached by the investigators in the event of a participant becoming suicidal or unreachable.
- •\- If of childbearing potential, has a negative pregnancy test at study entry and prior to each Treatment Session, and agrees to use adequate birth control through 10 days after the last Treatment Session
- •\- At Screening, has PTSD as diagnosed by a psychiatrist, with a symptom duration of 12 months or longer.
- •\- At Screening, is an active patient at the study site.
- •\- Has tried at least two conventional treatments (e.g. two forms of psychotherapy, two medications or a combination of the two) under the supervision of a healthcare professional.
Exclusion Criteria
- •\- Has borderline personality disorder with a history of associated psychotic decompensations.
- •\- Has evidence or history of significant hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, or any other medical disorder judged by the investigator to significantly increase the risk of MDMA.
- •\- Has a history of or current Diabetes Mellitus (Type 1 or 2\), hypothyroidism or glaucoma unless approval for study participation is received from the patient’s treating specialist.
- •\- Has active alcohol or substance use disorder.
- •\- Presents current suicide risk (i.e. current plan and intent).
- •\- Has symptomatic liver disease or has significant liver enzyme elevation.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Admiral: a study of the safety of multiple increasing doses of STK-001 in children and adolescents with Dravet syndromeDravet syndromeNervous System DiseasesEpilepsyISRCTN99651026Stoke Therapeutics, Inc19
Recruiting
Phase 3
A safety and efficacy study of GWP42003-P oral solution as adjunctive treatment for Japanese children and adults with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complexennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complexJPRN-jRCT2031220041Yamamoto Tomoyuki84
Active, not recruiting
Not Applicable
An open label study to determine the safety and tolerability oftwo dose escalation treatment regimens with an oral, delayed release preparation of nicotine in patients with stable ulcerative colitismaintained by steroid therapy. - NDlcerative colitisMedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerativeEUCTR2006-006052-35-ITS.L.A. PHARMA (UK) LTD
Completed
Not Applicable
Safety of turmeric-boswellia product in healthy peopleCTRI/2022/02/040107Arjuna Natural Private Limited
Completed
Not Applicable
To study the safety of Ashwagandha extract in healthy peopleCTRI/2022/08/044636Arjuna Natural Private Limited62